Physician

Swathi Singanamala, MD

According to 2025 Medicare claims, Swathi Singanamala, MD (NPI: 1023275617) practices nephrology in the Macon-Bibb County, GA market, with the plurality of this provider's patient population coming from Bibb, GA. This provider's primary affiliated billing organization is MACON MEDICAL GROUP PC (NPI: 1912914847; TIN: 58-2545719) and primary practice location at 31201-3206. Singanamala is affiliated with the TC2, LLC (ACO ID: A3365), participating under the MSSP model.

Singanamala's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,020 traditional Medicare patients, billed 14,631 HCPCS/CPT codes, and received $384,972 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,641 prescription claims across 720 beneficiaries totaling $280,514 in drug costs, led by Auryxia (Ferric Citrate). DME data shows 233 claims. Open Payments data shows 42 records totaling $810. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $69,806 to $280,514. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	693	8,120	$265,263
2016	765	13,891	$430,319
2017	930	15,808	$465,041
2018	873	14,162	$413,625
2019	1,069	41,941	$485,401
2020	905	13,511	$408,716
2021	1,080	15,040	$440,848
2022	1,195	18,311	$439,962
2023	1,074	15,741	$378,677
2024	1,020	14,631	$384,972

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	248	971	$69,806
2016	357	1,901	$138,812
2017	470	3,172	$280,052
2018	516	3,587	$204,313
2019	514	3,358	$191,689
2020	503	3,115	$242,343
2021	551	3,020	$275,958
2022	611	3,394	$220,785
2023	621	3,422	$527,014
2024	720	3,641	$280,514

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	59	$6,084
2021	N/R	N/R	N/R
2022	N/R	32	$551
2023	N/R	144	$2,811
2024	N/R	233	$6,802

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	757	1,178	$83
36415	Insertion of needle into vein for collection of blood sample	732	1,185	$9
80069	Kidney function blood test panel	723	1,161	$8
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	728	1,140	$8
81003	Automated urinalysis test	718	1,144	$2

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Auryxia	Ferric Citrate	23	1,104	$60,126
Veltassa	Patiromer Calcium Sorbitex	12	720	$22,861
Kerendia	Finerenone	11	990	$21,094
Farxiga	Dapagliflozin Propanediol	26	1,020	$19,668
Lokelma	Sodium Zirconium Cyclosilicate	18	695	$16,651

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7503	Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg	N	N/R	13	$2,873
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	48	$1,283
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	68	$1,016
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	36	$892
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	39	$715

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	42	$810	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Swathi Singanamala, MD?

Tedicare shows public-source Medicare data for Swathi Singanamala, MD (NPI 1023275617), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Swathi Singanamala, MD have ACO affiliation data?

Swathi Singanamala, MD is shown with ACO affiliation data for TC2, LLC (MSSP, ACO ID A3365).

What billing organization is linked to Swathi Singanamala, MD?

Swathi Singanamala, MD is linked to MACON MEDICAL GROUP PC (billing NPI 1912914847) in the available physician profile data.

Does Swathi Singanamala, MD have Open Payments data?

Swathi Singanamala, MD has 42 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.